Want to see GB:SYNC full AI Analyst Report?
Top Page
Syncona Shs GBP
(LSE:SYNC)
Select Model
Select Model
Rating:60Neutral
Price Target:
113.00 p
▲(5.61% Upside)
Action:Reiterated
Date:06/19/26
The score is anchored by balance-sheet strength (debt-free, large equity base), but is held back by inconsistent profitability and a recent drop of free cash flow to zero. Technicals are supportive with the price above major moving averages and positive MACD, while valuation remains constrained by losses implied by the negative P/E.
Positive Factors
Debt-free balance sheet
Zero reported total debt materially reduces financial risk and preserves strategic optionality. For an investment company that funds long clinical cycles, a debt-free structure enables Syncona to support portfolio companies through follow-on funding without immediate refinancing pressure, improving resilience across downturns and preserving ability to back high-conviction assets over multi-year horizons.
Negative Factors
Volatile profitability
Shifting from profit to multi-year losses signals inconsistent return generation from invested capital. For an investment company, unreliable profitability weakens the track record used to attract co-investors and can compress reinvestment capacity. Persistent losses also reduce visible evidence of repeatable value creation across portfolio cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported total debt materially reduces financial risk and preserves strategic optionality. For an investment company that funds long clinical cycles, a debt-free structure enables Syncona to support portfolio companies through follow-on funding without immediate refinancing pressure, improving resilience across downturns and preserving ability to back high-conviction assets over multi-year horizons.
Read all positive factors
Syncona Shs GBP (SYNC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£653.20M
Dividend YieldN/A
Average Volume (3M)483.92K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-40.88%
EPS Growth93.65%
CountryUK
Employees1,226
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.01
Shares Outstanding608,193,050
10 Day Avg. Volume510,558
30 Day Avg. Volume483,919
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)0.52
Price to Sales (P/S)9.39
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£189.00Price Target Upside76.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£49.14M
Syncona Shs GBP Business Overview & Revenue Model
Company Description
Syncona Ltd. is a closed-end investment fund, which engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. Its portfolio includes commercial companies, late-stage clinical...
How the Company Makes Money
Syncona makes money primarily through investment returns from its life-sciences portfolio rather than through selling products or services itself. Its key economic driver is the change in value of its holdings (net asset value), which can increase...
Syncona Shs GBP Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
53
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 57.34M | -68.31M | 30.75M | -39.79M | 18.69M |
| Gross Profit | 43.36M | -68.31M | 14.10M | -51.91M | 3.68M |
| EBITDA | -8.80M | -143.16M | 8.14M | 0.00 | 11.15M |
| Net Income | -8.80M | -143.16M | 3.79M | -56.02M | 8.84M |
Balance Sheet | |||||
| Total Assets | 1.05B | 1.06B | 1.25B | 1.27B | 1.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92M | 1.11M | 261.00K | 11.00K | 276.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 14.95M | 11.79M | 12.22M | 13.76M | 23.55M |
| Stockholders Equity | 1.04B | 1.05B | 1.24B | 1.25B | 1.31B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 43.91M | 20.47M | -265.00K | 262.00K |
| Operating Cash Flow | 23.33M | 43.91M | 20.47M | -265.00K | 262.00K |
| Investing Cash Flow | -15.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -6.78M | -43.06M | -20.22M | 0.00 | 0.00 |
Syncona Shs GBP Technical Analysis
Positive
107.00
Price Trends
104.19
Positive
98.24
Positive
97.69
Positive
Market Momentum
0.81
Positive
54.34
Neutral
54.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Positive. The current price of 107 is above the 20-day moving average (MA) of 106.70, above the 50-day MA of 104.19, and above the 200-day MA of 97.69, indicating a bullish trend. The MACD of 0.81 indicates Positive momentum. The RSI at 54.34 is Neutral, neither overbought nor oversold. The STOCH value of 54.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SYNC.
Syncona Shs GBP Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £2.03B | 15.50 | 4.51% | 2.02% | 68.95% | 109.67% | |
72 Outperform | £1.49B | 12.92 | 14.60% | 8.21% | -22.64% | 58.92% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
65 Neutral | £1.18B | 10.11 | 9.21% | ― | -78.12% | 30945.45% | |
60 Neutral | £653.20M | -74.58 | -9.02% | ― | -40.88% | 93.65% | |
58 Neutral | £625.47M | 9.28 | 7.16% | ― | -35.12% | ― | |
52 Neutral | £112.67M | -13.18 | -4.78% | 3.67% | -2.25% | -350.00% |
* Financial Sector Average
GB:SYNC
Syncona Shs GBP
107.40
11.80
12.34%
GB:ASHM
Ashmore Group PLC
228.00
68.72
43.14%
GB:GROW
Molten Ventures
687.50
321.70
87.94%
GB:IPO
IP Group plc
69.30
10.90
18.66%
GB:MERC
Mercia Asset Management
26.75
-4.77
-15.13%
GB:CLDN
Caledonia Investments
396.50
20.24
5.38%
Syncona Shs GBP Corporate Events
Business Operations and StrategyFinancial Disclosures
Syncona Highlights Portfolio Progress and Prepares for Key Value Milestones
Positive
Aug 6, 2026
Syncona reported first-quarter net assets of £1,038.1 million, with its Life Science Portfolio rising to £866.7 million and capital deployment concentrated entirely in late-stage and clinical-stage companies, notably Spur Therapeutics an...
Business Operations and StrategyRegulatory Filings and Compliance
Syncona Updates Total Voting Rights and Share Capital Structure
Neutral
Aug 3, 2026
Syncona Limited has reported that as of 31 July 2026 it has 672,558,750 ordinary shares in issue, of which 64,356,396 are held in treasury and carry no voting rights. This leaves 608,202,354 voting rights in the company, a key figure investors mus...
Business Operations and StrategyRegulatory Filings and Compliance
Syncona Issues New Shares Under Long‑Term Incentive Scheme
Neutral
Jul 23, 2026
Syncona Ltd has announced the issue of 9,330 new ordinary shares, equivalent to about 0.002% of its existing share capital, to satisfy awards under its long‑term incentive scheme. The new shares will rank pari passu with existing ordinary sh...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Syncona Publishes 2026 Annual Report and Sets August AGM
Neutral
Jul 3, 2026
Syncona Ltd, the U.K.-listed life sciences investor, has released its Annual Report and Accounts for the year to 31 March 2026 alongside the formal notice of its 2026 Annual General Meeting. The documents have been filed with the Financial Conduct...
Other
Syncona Director Increases Stake with Share Purchase on London Stock Exchange
Positive
Jun 22, 2026
Syncona Limited reported that non-executive director John Patrick Roche purchased 16,063 ordinary shares of the company on 19 June 2026 at a price of £0.996 per share on the London Stock Exchange. The transaction, conducted in British pounds,...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
Syncona Sets £250m Return Target as Portfolio Advances to Late-Stage Trials
Positive
Jun 18, 2026
Syncona reported largely stable full-year results, with net assets of £1.04 billion and modest gains in its life sciences portfolio driven by a valuation uplift at Beacon Therapeutics following an oversubscribed Series C financing. The group ...
Business Operations and StrategyExecutive/Board Changes
Syncona appoints veteran investment specialist Norman Crighton to board
Positive
Jun 17, 2026
Syncona Ltd has appointed veteran investment company specialist Norman Crighton as an independent non-executive director from 1 July 2026, adding more than three decades of experience in investment banking, fund management and board governance to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.